ASCO2024 Archives - Geneseeq Technology Inc. | A Precision Oncology Company /tag/asco2024/ We see precision medicine as the future of cancer care. Let’s accelerate precision cancer care, together. Wed, 28 May 2025 19:24:48 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 /wp-content/uploads/2019/09/geneseeq-fav.png ASCO2024 Archives - Geneseeq Technology Inc. | A Precision Oncology Company /tag/asco2024/ 32 32 Geneseeq AT ASCO 2024 /geneseeq-at-asco-2024/ /geneseeq-at-asco-2024/#respond Tue, 14 May 2024 14:00:47 +0000 /?p=87975 The American Society of Clinical Oncology (ASCO) Annual Meeting stands as one of the most influential gatherings in clinical oncology, […]

The post Geneseeq AT ASCO 2024 appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

]]> The American Society of Clinical Oncology (ASCO) Annual Meeting stands as one of the most influential gatherings in clinical oncology, offering a critical platform for presenting clinical studies that have the potential to shape future practice and research. This year, ASCO will be held from May 31st to June 4th, 2024 in Chicago Illinois. Geneseeq will participate in the ASCO with five interesting topics covering the identification of novel biomarkers and early detection of diverse cancer types.

 

The following is a summary of our studies that will be presented at ASCO 2024：

Poster 1 (Bd# 276) A multi-center study for colorectal cancer early detection among patients with high-risk disease using a cell-free fragmentomics assay.

Poster 2 (Bd# 34) Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.

Poster 3 (Bd# 153) Fragmentomics of cell-free DNA as a sensitive biomarker for early detection of pancreatic cancer.

Poster 4 (Bd# 83) Molecular characterization and biomarker identification in pediatric B-cell acute lymphoblastic leukemia.

Poster 5 (Bd# 460) Genomic profiling of non-small cell lung cancer with rare aberrations in EGFR codon L858 and the survival outcome under real-world first-line EGFR tyrosine kinase inhibitor treatment compared to classic EGFRL858R

The post Geneseeq AT ASCO 2024 appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

]]> /geneseeq-at-asco-2024/feed/ 0